美国 · 股市与财经 · The Motley Fool
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.
Evidence from two large-scale studies (NHS-Galleri in England and a 35,878-enrollment study in the U.S., (PATHFINDER 2) shows that Galleri performs better on the 12 deadly cancers…
在 The Motley Fool 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.fool.com)





